Stefan Van Grieken, CEO and co-founder of Cradle, dives into the groundbreaking fusion of AI and protein engineering. He discusses the crucial functions of proteins in biology and how Cradle’s software is reshaping protein design for therapeutics and industrial use. The conversation also explores the ethical implications of this technology, challenges like immunogenicity, and the potential for sustainable solutions via AI. With insights into the future of biotech, Van Grieken highlights how machine learning could lower innovation barriers in drug development.

Stef van Grieken, Co-founder and CEO of Cradle, spearheads AI innovations in protein engineering for drug development. They delve into the rapid growth of Cradle, fueled by a $100M funding round, and discuss the complexities of AI's integration into drug discovery. Stef highlights the challenges of selling SaaS to pharma and the critical need for effective lab automation. With insights into future trends, he explores what the next 25 years hold for biotechnology and the evolving landscape of AI-driven drug development.